Contact
Please use this form to send email to PR contact of this press release:
AAD 2023: Late-Breaking Phase III Results Demonstrate nemolizumab's Significant Impact on Prurigo Nodularis
TO:
Please use this form to send email to PR contact of this press release:
AAD 2023: Late-Breaking Phase III Results Demonstrate nemolizumab's Significant Impact on Prurigo Nodularis
TO: